(7) It has been shown that MANF performs better than CDNF and GDNF in pre clinical trials.
(8) GDNF was owned by a company purchased for $250 Million during pre-clinical trials.
WIDELY known AND baked into current AMBS pps.
(8) Is more of a cautionary to any JV or buyout candidate to NOT overvalue MANF, as the clinical path, including the results from human clinical trials, is anything but certain.
Market Data 
Markets 
AI
